These results indicated that SAP administration would ameliorate self-DNA-induced lupus nephritis via regulating pathogenic anti-dsDNA antibody production and inflammation in lupus mice, which might provide SAP as a potential therapeutic strategy for self-antigen induced SLE and other autoimmune disease. This evidence concerns the gene APCS and systemic lupus erythematosus.